Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical Officer

NEXT STORY
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO
PREV STORY
Le Dr Benjamin Musher présidera l’étude de phase 1-2 évaluant le traitement anticancéreux Natrunix™ de XBiotech contre le cancer du pancréas
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain

Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through  ...

author_avatar
NASDAQ Market News

Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role

SANTA CLARA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary ...

author_avatar
NASDAQ Market News

Cesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) Services

RANCHO CORDOVA, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), ...

author_avatar
NASDAQ Market News